A Clear Path Ahead
IMV Inc. (Nasdaq: IMV) (TSX: IMV) has the potential to fundamentally transform the way we use our immune system to address a broad range of serious diseases. We continue to build value in our Company by establishing collaborations with leading biotechnology and pharmaceutical companies; advancing our clinical programs; and seeking additional opportunities to leverage our novel formulation technology in underserved markets.
- November 27, 2019 at 7:05 AM EST
Events, Webcast and Presentations
Dec 9, 2019 at 8:00 AM EST
Clinical update on Investigator-initiated SPiReLPhase 2 with Merck’s Keytruda® in relapse/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL)
Dec 11, 2019 at 4:20 PM EST
IMV – LD Micro Main Event XII Presentation